Abstract: Afatinib, a second-generation oral tyrosine kinase inhibitor (TKI), is suitable for first-line treatment of advanced non-small-cell lung cancer (NSCLC) and second-line treatment of squamous NSCLC. At present, a large number of strong clinical research data has confirmed the efficacy and safety of afatinib. Therefore, this article reviews the mechanism of action, pharmacokinetic clinical efficacy, combination of drugs, adverse reactions and dose adjustment of afatinib in order to provide ideas for individual rational drug use guidance.

Key words: afatinib, lung cancer, clinical efficacy, drug combination, adverse reactions